The specialist drug development Company delivering targeted small
molecule therapeutics to improve the treatment of cancer and autoimmune
diseases announces encouraging top-line results from its UKRI grant funded
Covid-19 research project. The project has completed on schedule, with the
final results confirming the initial encouraging results as noted in the
Company’s Interim Results, published on 23 April 2021. The results of the
project found that SDC-1801 reduced the levels of cytokines ....
